Invisiblu Recalls LGD-Xtreme Capsules Due to Unapproved Drug
Invisiblu International LLC recalls LGD-Xtreme capsules containing unapproved ligandrol LGD-4033. Check lot #21511166.
Stop using this now
Marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033
Contact the company
What happened, in plain English
Invisiblu International LLC is recalling LGD-Xtreme, a 3 mg capsule product manufactured for Continuum Labs. The recall is necessary because the product contains ligandrol LGD-4033, which is an unapproved drug marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). This specific batch was distributed nationwide in the United States and in Brazil. Read more at govinfonow.com/recall/43018-invisiblu-recalls-lgd-xtreme-capsules-due-to-unapproved-drug.
Source Summary by GovInfoNow · govinfonow.com/recall/43018-invisiblu-recalls-lgd-xtreme-capsules-due-to-unapproved-drug · Updated October 11, 2026 · FDA enforcement record: FDA #D-0910-2016
Cite this page
“Invisiblu Recalls LGD-Xtreme Capsules Due to Unapproved Drug.” GovInfoNow, updated October 11, 2026. https://govinfonow.com/recall/43018-invisiblu-recalls-lgd-xtreme-capsules-due-to-unapproved-drug. Based on FDA recall #D-0910-2016 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0910-2016%22&limit=1).
Why it’s dangerous
The product contains ligandrol LGD-4033, which is not an approved drug ingredient under federal regulations. Because it was marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), its safety and efficacy have not been verified by the FDA.
Who’s affected
Consumers who purchased LGD-Xtreme capsules, specifically those with lot number 21511166 and an expiration date of 11/18. Individuals who bought the product in the United States or Brazil are affected.
How to tell if you have this one
Look for a 90-count bottle of LGD-Xtreme (ligandrol LGD-4033) capsules, 3 mg. Check the label for lot number 21511166 and an expiration date of 11/18. The product was manufactured for Continuum Labs in Fort Lauderdale, FL.
- Brand
Invisiblu International- Category
Drug
Where it went and when
Where it was distributed
Distributed nationwide, and outside the U.S.
FDA distribution: “Nationwide and Brazil.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide, and outside the U.S.
Recall timeline
FDA published this recall 2 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0910-2016 (March 31, 2016) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0910-2016 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.